Results 21 to 30 of about 3,032 (163)
PAC1 Receptors: Shapeshifters in Motion [PDF]
Journal of Molecular Neuroscience, 2018 Shapeshifters, in common mythology, are entities that can undergo multiple physical transformations. As our understanding of G protein-coupled receptors (GPCRs) has accelerated and been refined over the last two decades, we now understand that GPCRs are not static proteins, but rather dynamic structures capable of moving from one posture to the next ...
Chenyi Liao, Victor May, Jianing Li
openaire +2 more sources
Acta Biochimica et Biophysica Sinica, 2022 As a neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP)-preferring receptor, PAC1-R mediates effective neuroprotective activity.
Fan Guangchun +4 more
doaj +1 more source
Neuroendocrine Tumors Express PAC1 Receptors [PDF]
Annals of the New York Academy of Sciences, 2006 Abstract: Neuroendocrine tumors (NETs) of the gastrointestinal tract can be grossly divided into two general types: carcinoid and pancreatic endocrine tumors. The former develop in the luminal intestine whereas the latter occur within the pancreas. To ascertain whether pituitary adenylate cyclase‐activating polypeptide (PACAP) has a biological effect ...
Song N, Lieu +3 more
openaire +2 more sources
Applied Sciences, 2021 Regeneration of peripheral nerves depends on the ability of axons to navigate through an altered extracellular environment. It has been suggested that Schwann cells facilitate this process through their secretion of neuropeptides and proteases. Using the
Sarah Thomas Broome +2 more
doaj +1 more source
ASN Neuro, 2023 The mechanism of light-induced spatial memory deficits, as well as whether rhythmic expression of the pituitary adenylyl cyclase-activating polypeptides (PACAP)-PAC1 pathway influenced by light is related to this process, remains unclear.
Dejiao Xu +10 more
doaj +1 more source
Neurobiology of Disease, 2021 Chronic inflammation drives synaptic loss in multiple sclerosis (MS) and is also commonly observed in other neurodegenerative diseases. Clinically approved treatments for MS provide symptomatic relief but fail to halt neurodegeneration and neurological ...
Christina Van +11 more
doaj +1 more source
Positive allosteric regulation of PAC1-R up-regulatesPAC1-R and its specific ligand PACAP
Acta Biochimica et Biophysica Sinica, 2022 PAC1-R is a recognized preferential receptor for the neuropeptide of pituitary adenylate cyclase-activating polypeptide (PACAP), which mediates neuroprotective and nerve regenerative activities of PACAP.
Fan Guangchun +4 more
doaj +1 more source
Maxadilan, a PAC1 receptor agonist from sand flies [PDF]
Peptides, 2007 In 1991, a potent 61 amino acid vasodilator peptide, named maxadilan, was isolated from the salivary glands of the sand fly. Subsequently, it was shown that this peptide specifically and potently activated the mammalian PAC1 receptor, one of the three receptors for PACAP. These studies and the link between maxadilan and leishmaniasis are discussed.
Ethan A, Lerner +2 more
openaire +2 more sources
Frontiers in Cellular Neuroscience, 2021 Pituitary adenylyl cyclase-activating polypeptide (PACAP) is a member of the vasoactive intestinal polypeptide (VIP)-the secretin-glucagon family of neuropeptides. They act through two classes of receptors: PACAP type 1 (PAC1) and type 2 (VPAC1 and VPAC2)
Jérôme Ruel +8 more
doaj +1 more source
Molecular Basis of Class B GPCR Selectivity for the Neuropeptides PACAP and VIP
Frontiers in Molecular Biosciences, 2021 The related neuropeptides PACAP and VIP, and their shared PAC1, VPAC1 and VPAC2 receptors, regulate a large array of physiological activities in the central and peripheral nervous systems.
Chenyi Liao +4 more
doaj +1 more source